Theromics

Executive Summary

Theromics is a Cambridge-based biotechnology company pioneering a novel thermal accelerant platform to improve the efficacy and predictability of ablation therapies and localized drug delivery. Its core technology, comprised of injectable nanogels HeatSYNC™ (for heat-based ablation) and CryoSYNC™ (for cryoablation), amplifies energy transfer within target tissues, enabling larger, more uniform ablation zones and facilitating combination therapies with chemotherapeutics or immunomodulators. Founded in 2016 as a spin-out from Brown University, the company addresses a significant unmet need in oncology and interventional radiology, where current ablation techniques are often limited by inconsistent lesion sizes and incomplete tumor destruction. Theromics’ technology has the potential to transform ablation into a more reliable, minimally invasive treatment modality, expand its applicability to hard-to-treat tumors, and create a platform for synergistic drug-device combinations. While still in a preclinical or early clinical stage, the company’s novel approach has attracted interest from key opinion leaders and strategic partners in the interventional oncology space. Theromics is well-positioned to capitalize on the growing adoption of image-guided tumor ablation and the shift toward localized, combination therapies that minimize systemic side effects.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial for HeatSYNC70% success
• Q1 2027Strategic Partnership or Licensing Deal with Major Ablation Device Manufacturer50% success
• Q3 2026Publication of Pivotal Preclinical Data in Peer-Reviewed Journal85% success